The Flower Behind Vincristine: A Chance Discovery in Hematologic Cancer Therapy

Vincristine, central to childhood leukemia treatment, is part of a remarkable story that began with a flower being investigated for diabetes.

The Madagascar periwinkle, Catharanthus roseus, had a long history in traditional medicine, especially as a supposed remedy for diabetes. In the 1950s, scientists began testing plant extracts for this effect. The expected decrease in blood glucose never appeared. Instead, experimental animals developed profound leukopenia and bone marrow suppression. That toxicity redirected the research toward cancer, with vinblastine and vincristine later entering oncology.

With the rise of molecularly targeted drugs, antibodies and cellular therapies, a plant-derived cytotoxic agent still holds an important place in the treatment of acute lymphoblastic leukemia (ALL), several lymphoid malignancies, and solid tumors.

The Madagascar Periwinkle Was Not Being Studied for Cancer

Catharanthus roseus is native to Madagascar, though cultivation spread the plant throughout tropical and subtropical regions. Older scientific literature called it Vinca rosea, that’s why its anticancer compounds became known as vinca alkaloids.

The plant produces an unusually diverse collection of specialized metabolites, more than 200 alkaloids, likely serving ecological functions that help it survive in its environment. Researchers, who led that original diabetes work at the University of Western Ontario, followed up on the leukopenia instead of abandoning the project. Their experiments against transplanted leukemia in mice led to the isolation of an active alkaloid, vinblastine, and their paper captured the unusual route to the discovery in its title: “Role of Chance Observations in Chemotherapy: Vinca rosea.”

A separate program at Eli Lilly was investigating the same plant. Researchers there screened plant-derived compounds and isolated additional alkaloids, including vincristine.

Vinblastine and Vincristine: Similar, but Different in Practice

Vinblastine is formed from two alkaloids produced by Catharanthus roseus, catharanthine and vindoline, which are joined through the plant’s complex biosynthetic pathway. Vincristine is closely related, with a small structural difference, that also changes its pharmacology and toxicity.

Vinblastine found roles in Hodgkin lymphoma and several solid tumors, vincristine became central to ALL, other lymphoid malignancies, and pediatric solid cancers. Vincristine causes less myelosuppression, making it easier to combine with other marrow-suppressive drugs. Its main liability is neurotoxicity.

Childhood ALL became one of the best examples of the value of combination therapy, with drugs acting through different paths: vincristine alongside glucocorticoids, antimetabolites, asparaginase, anthracyclines and other agents incorporated as treatment evolved.

How Vincristine Disrupts a Leukemia Cell

Vincristine acts on microtubules, the dynamic structures built from tubulin that cells need both to segregate chromosomes during division and for several functions outside mitosis. By binding tubulin and disrupting microtubule dynamics, it breaks down the mitotic spindle, blocking normal cell division and promoting cell death.

The description of vincristine as a drug that “arrests cells in metaphase” does not capture the whole. Studies in primary ALL cells have shown that some undergo mitotic arrest, when others die without first entering mitosis. So, microtubule disruption outside mitosis may play a role too, affecting intracellular trafficking, organelle positioning and protein transport.

Leukemia cells can also become less sensitive. Some pump the drug out through increased drug-efflux transporters, others change their tubulin or microtubule dynamics. Either way, it’s why vincristine works best as one part of multidrug therapy.

Why Does Hematology Still Rely on Vincristine?

Vincristine has outlasted several generations of cancer therapy. ALL treatment has advanced with molecular classification, measurable residual disease assessment, targeted therapies and immunotherapy, but it remains part of many contemporary regimens like Hyper-CVAD, mini-Hyper-CVD, and pediatric-inspired ALL protocols.

Vincristine is also part of established lymphoma regimens, most recognizably CHOP and R-CHOP, where the “O” stands for Oncovin, its original trade name. The longevity comes from a mechanism distinct from companion drugs, limited myelosuppression, and decades of evidence backing its use in combination therapy. Newer agents have reduced its role in some settings, but have not replaced it outright.

That dependence became visible during the 2019 US vincristine shortage. After one manufacturer left the market and supply became constrained, pediatric oncology centers faced potential dose rationing.

Vincristine’s Major Toxicity

Microtubules are essential not only to malignant cells. In neurons, they provide structural tracks for transport of proteins, organelles and vesicles along long axons. Disrupting this causes vincristine’s characteristic dose-limiting toxicity – peripheral neuropathy.

It can involve sensory, motor and autonomic nerves. Patients may develop paresthesia, neuropathic pain, loss of reflexes, distal weakness or gait abnormalities. Autonomic involvement can produce constipation and even ileus. Cranial neuropathies are less common but well recognized.

Patients receiving similar doses can experience very different degrees of neuropathy. Cumulative exposure contributes, and pre-existing neurologic disease increases the risk, but clinical variables alone do not identify every patient who will develop toxicity.

Drug interactions are important. Vincristine is metabolized through CYP3A pathways, and strong inhibitors can increase its exposure and toxicity. Azole antifungals, mainly itraconazole and voriconazole, have been associated with severe neurotoxicity: a practical hardship when antifungal therapy is needed during the course.

Can Vincristine Neurotoxicity Be Predicted?

Pharmacogenomic studies have looked at variants affecting drug metabolism, transport, and neuronal or cytoskeletal function. The best-known candidate is CEP72, a gene involved in microtubule organization: some studies link a CEP72 promoter variant to greater risk or severity of vincristine-induced neuropathy.

CYP3A5, ABCB1 and other genes involved in vincristine disposition have also been investigated, but results haven’t been consistent enough across populations to support a genetic test that guides dosing. Prospective studies combining genetics, pharmacokinetics and standardized neuropathy assessment may get there eventually.

Can Synthetic Biology Reproduce Vinca Alkaloids?

Vinca alkaloids occur in the plant at low concentrations and come from an unusually complex biosynthesis, which has made chemical synthesis difficult as a practical alternative. This is part of why researchers have tried reproducing that in microorganisms instead.

In 2022, researchers reported in Nature that they had engineered yeast to produce catharanthine and vindoline de novo. Reconstructing the pathway required 30 enzymatic steps beyond native yeast metabolism and 56 genetic edits, including 34 genes taken from plants. The compounds could then be used to produce vinblastine through semisynthesis.

This didn’t mean vinca alkaloids could suddenly be brewed in industrial fermenters, and it hasn’t replaced plant-based manufacturing. But it showed that some precursors could be produced in engineered microbes, with subsequent work improving the process and potentially opening the door to more reliable supply and new analogues.

Vincristine and vinblastine are only two of more than 200 alkaloids found in a single plant species, a reminder that biodiversity is also a largely unexplored library of chemistry. An experiment that failed to confirm an antidiabetic effect instead led to a cancer drug that still matters in oncology.

You can also read about